Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03781479 |
Recruitment Status :
Completed
First Posted : December 20, 2018
Results First Posted : June 1, 2021
Last Update Posted : June 1, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Muscular Atrophy, Spinal | Drug: Amifampridine Phosphate Drug: Placebo Oral Tablet | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3 |
Actual Study Start Date : | January 21, 2019 |
Actual Primary Completion Date : | July 23, 2020 |
Actual Study Completion Date : | July 23, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Amifampridine Phosphate - Placebo
Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
|
Drug: Amifampridine Phosphate
Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Other Name: 3,4 diaminopyridine phosphate Drug: Placebo Oral Tablet Placebo Oral Tablet |
Experimental: Placebo - Amifampridine Phosphate
Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
|
Drug: Amifampridine Phosphate
Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
Other Name: 3,4 diaminopyridine phosphate Drug: Placebo Oral Tablet Placebo Oral Tablet |
- Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis [ Time Frame: Screening, the first (Day 1) and last day (Day 0) of the Run-in period, during Period 1 at Day 7 and Day 14, and during Period 2 at Day 21 and Day 28 ]Hammersmith Functional Motor Scale Expanded (HFMSE) assesses motor function by functional item in order of progressive difficulty, with higher values showing higher function abilities. Each item is scored on a scale of 0-2 with 2 representing item achieved unaided and 0 representing inability to achieve item. Each item was assessed by the patient at Screening, the first (Day 1) and last day (Day 0) of the Run-in period, during Period 1 at Day 7 and Day 14, and during Period 2 at Day 21 and Day 28. The total HFMSE score was calculated as the sum of each item score, with a maximum score of 66 (all items achieved unaided) and minimum score of 0 (all items failed). Change from baseline (CFB) will be assessed from Day 0 to Day 28. A mixed effects liner model was fit with the HFMSE change from baseline (CFB) scores at Day 28 as a response and treatment, sequence, and treatment by sequence as fixed effect terms and patient as a random effect.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 50 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Willing and able to provide written informed consent after the nature of the study has been explained and before the start of any research-related procedures.
- Male or female between the ages of 6 and 50 years.
- Genetically confirmed diagnosis of SMA Type 3.
- Able to walk independently for at least 30 meters.
- Not taking Nusinersen for the treatment of SMA (Nusinersen should be stopped at least 6 months before screening). Salbutamol is permitted only if the dose has been stable during the 6 months before screening.
- Able to swallow oral medication.
- Female patients of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin [HCG] at Screening); and must practice an effective, reliable contraceptive regimen during the study and for up to 30 days following discontinuation of treatment.
- Ability to participate in the study based on overall health of the patient and disease prognosis, as applicable, in the opinion of the Investigator; and able to comply with all requirements of the protocol, including completion of study questionnaires.
Exclusion Criteria:
- Epilepsy and currently on medication for epilepsy.
- Concomitant use of medicinal products with a known potential to cause QTc prolongation.
- Patients with long QT syndromes.
- An electrocardiogram (ECG) within 6 months before starting treatment that shows clinically significant abnormalities, in the opinion of the Investigator.
- Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.
- Treatment with an investigational drug (other than amifampridine), device, or biological agent within 6 months prior to Screening or while participating in this study.
- Surgery for scoliosis or joint contractures within the previous 6 months.
- Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.
- History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).
- Less than a 3-point improvement in HFSME from start of the Open label Run -in period to end of Run-in (Day 0).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03781479
Italy | |
Neurological Institute Carlo Besta | |
Milano, Lombardy, Italy, 20133 |
Principal Investigator: | Lorenzo Maggi, MD | Carlo Besta Institute, Milan, Italy |
Documents provided by Catalyst Pharmaceuticals, Inc.:
Responsible Party: | Catalyst Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT03781479 |
Other Study ID Numbers: |
SMA-001 |
First Posted: | December 20, 2018 Key Record Dates |
Results First Posted: | June 1, 2021 |
Last Update Posted: | June 1, 2021 |
Last Verified: | May 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Type 3 |
Muscular Atrophy Muscular Atrophy, Spinal Atrophy Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Spinal Cord Diseases Central Nervous System Diseases Motor Neuron Disease |
Neurodegenerative Diseases Neuromuscular Diseases Amifampridine Neuromuscular Agents Peripheral Nervous System Agents Physiological Effects of Drugs Potassium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |